-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Opinion|Videos|April 14, 2025

Evaluating Ruxolitinib In An 18-Month Retrospective Claims Analysis

Panelists discuss how an 18-month retrospective claims analysis evaluated ruxolitinib's real-world effectiveness in atopic dermatitis, demonstrating sustained disease control, reduced healthcare utilization, decreased steroid dependency, improved medication adherence, and consistent safety outcomes across diverse patient demographics and disease severities compared to conventional treatments.


Related to this article

2.3 million reasons to rethink member communications before Jan. 1
CMS projects roughly 2.3 million people will lose Medicaid coverage in 2027 under the new community engagement requirements, also referred to as work requirements: four in ten to paperwork, not noncompliance. Arkansas showed how that happens; here is what plans can learn before the clock starts.